Filing Flows › Pacira BioSciences (PCRX) › Free cash flow
Pacira BioSciences (PCRX) free cash flow by quarter
Pacira BioSciences' free cash flow was $46.4M in Q3 2026 (third quarter 2026), -17% from Q2 2026. Over the last 7 quarters it ranged from $9.3M (Q2 2025) to $57.0M (Q3 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $46.4M | -17% | -18% |
| Q2 2026 | $56.1M | +144% | +503% |
| Q1 2026 | $23.0M | -47% | -15% |
| Q4 2025 | $43.5M | -24% | — |
| Q3 2025 | $57.0M | +512% | — |
| Q2 2025 | $9.3M | -65% | — |
| Q1 2025 | $26.9M | — | — |
Q3 2026 at a glance
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Pacira BioSciences' free cash flow?
Pacira BioSciences' free cash flow was $46.4M in Q3 2026 (third quarter 2026), -17% from Q2 2026.
How has Pacira BioSciences' free cash flow changed?
Over the last 7 quarters it ranged from $9.3M (Q2 2025) to $57.0M (Q3 2025).